TYRP1 and neoplasm: However, a relatively uniform minimum of 80% CD47 repression achieved through CRISPR interference (CRISPRi), combined with the ineffective monoclonal antibody (anti-Tyrp1), enables phagocytosis to dominate net growth, triggering an effective anti-tumor immune response [73].